A SAFETY AND TOLERABILITY STUDY OF ASSISTED AND SELF-ADMINISTERED SUBCUTANEOUS (SC) HERCEPTIN (TRASTUZUMAB) AS ADJUVANT THERAPY IN EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER: